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Ischemia Dictates Outcome,
Not Symptoms*
Peter H. Stone, MD
Boston, Massachusetts
There has been enormous interest in determining whether
the presence or absence of symptoms of myocardial ischemia
influence prognosis in patients with coronary artery disease
(CAD). The concern has been predicated on the concept
that the anginal pain associated with ischemia serves as a
safety warning signal indicating the presence of myocardial
ischemia and that the absence of a warning signal may
enable the patient to continue exercise or emotional stress
despite ischemia, exacerbate the dangerous imbalance of
myocardial oxygen supply and demand, and potentially
cause an ischemia-associated arrhythmia or acute coronary
syndrome. These concerns have been further fueled by the
appreciation that the vast majority of ischemic episodes in
coronary patients are indeed asymptomatic. The prognostic
significance of painless ischemia is particularly germane in
the management of patients with diabetes because they are
at increased risk for the presence of painless myocardial
ischemia (1).
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The mechanisms responsible for why some episodes of
ischemia are asymptomatic and why some coronary pa-
tients’ ischemia is consistently asymptomatic have re-
mained unclear. Possible mechanisms have included
asymptomatic ischemia being less severe than symptom-
atic ischemia (2), presence of endogenous opiates that
may blunt the perception of cardiac ischemia (3), and
abnormal brain processing of afferent pain messages from
the heart (4). Autonomic nerve dysfunction may also be
responsible for the lack of perception of ischemic symp-
toms (5), particularly among patients with diabetes, and
such autonomic neuropathy is indeed associated with
increased mortality and morbidity (6).
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and consequently the most optimal management strategy
for such patients, has been an important clinical question
since the first appreciation that myocardial ischemia was
frequently asymptomatic. The Coronary Artery Surgery
Study Registry of patients enrolled from 1974 to 1979 was
the first major study indicating that the 7-year survival was
dependent not on the presence of anginal symptoms accom-
panying exercise-induced ischemia but on the severity and
extent of coronary obstructions (7). Ischemia identified
during ambulatory electrocardiographic (ECG) monitoring
of patients with CAD, which is almost always asymptomatic
(even in typically symptomatic patients), also identifies
patients at increased risk of adverse cardiac events. The
ACIP (Asymptomatic Cardiac Ischemia Pilot) study sug-
gested, in a relatively small number of patients, that the
2-year incidence of death and myocardial infarction (MI)
was significantly lower among patients randomized to an
early revascularization strategy (percutaneous coronary in-
tervention [PCI] or coronary artery bypass graft [CABG])
compared with patients randomized to an early pharmaco-
logical strategy, whether based on control of angina or
control of ischemia (8).
In this issue of the Journal, Dagenais et al. (9) provide
important new data concerning the prognostic significance
of the presence of anginal symptoms on outcomes over a
5-year follow-up in the BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) study during
the enrollment period from 2001 to 2005. They performed
a post hoc analysis of 2,364 patients with type 2 diabetes and
documented CAD: 1,434 patients with typical angina
symptoms; 506 with anginal equivalent of dyspnea, fatigue,
or diaphoresis on exertion; and 424 patients with truly
asymptomatic ischemia. All patients received optimal med-
ical therapy consisting of lifestyle management targeting
smoking cessation, diet, weight loss, and regular physical
exercise, and pharmacological therapy to maintain glycosy-
lated hemoglobin 7%, low-density lipoprotein 100 mg/dl,
and blood pressure 130/80 mm Hg. Patients were ran-
domly assigned to a treatment strategy of prompt coronary
revascularization with optimal medical therapy or optimal
medical therapy alone and assigned to undergo either
insulin sensitization therapy or insulin provision therapy.
Dagenais et al. (9) performed 2 analyses to determine the
role of symptom status in outcome and response to assigned
strategy: all study patients analyzed together, using statisti-
cal adjustments to account for effects of confounders includ-
ing the assigned management strategy, and outcomes ana-
lyzed separately within each management treatment strategy
on the basis of symptom status. They observed in each
analysis that there was no difference in the composite of
all-cause death, nonfatal MI, or nonfatal stroke among the
3 groups based on the anginal symptoms at baseline, even
though the asymptomatic ischemia group had the greatest
magnitude of myocardium at risk compared with the other
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study was a post hoc analysis, it serves primarily to generate
new hypotheses; however, they nevertheless conclude that
asymptomatic patients with type 2 diabetes, stable CAD,
and documented ischemia were at as high risk as similar
patients with anginal symptoms and that all of these
patients should be managed similarly in terms of risk
stratification and preventive therapies.
How do we incorporate these important findings into
clinical care? Should we now aggressively screen all patients
with diabetes to determine if CAD and ischemia are
present, even those without any symptoms to suggest
ischemia, because prognosis is related to ischemic risk and
not to anginal symptoms? The prospective studies available
to date have not been conclusive in regard to the value of
widespread screening of all patients with diabetes to identify
those with CAD because the studies have been small, there
has been a low prevalence of high-risk CAD in the patients
investigated, and the study designs have not included
rigorous diagnostic and management strategies (10). Fur-
thermore, the best management strategy once CAD is
identified in the patient with diabetes remains somewhat
unclear in that the main BARI 2D trial indicated no survival
advantage for revascularization as opposed to medical ther-
apy (11). If revascularization therapy is the preferred strat-
egy in high-risk patients with diabetes and multivessel
CAD, the recently reported FREEDOM (Future Revascu-
larization Evaluation in Patients With Diabetes Mellitus:
Optimal Management of Multivessel Disease) trial indi-
cated that CABG surgery reduced the rate of the primary
endpoint of death, nonfatal MI, or nonfatal stroke com-
pared with PCI (12). Given the rapidly escalating epidemic
of type 2 diabetes, the costs of widespread CAD screening
of low-risk asymptomatic patients with diabetes would
likely outweigh the minor clinical benefit (10).
For now, we should certainly optimize risk factor man-
agement for all patients with diabetes, and we will need
more prospective cost-effectiveness studies to determine an
optimal risk stratification strategy for patients with diabetes
at risk for CAD. Stepwise risk stratification will likely be the
appropriate way to evaluate CAD risk, with careful assess-
ment of risk factors and diagnostic modalities such as stress
ECG testing, myocardial perfusion imaging, and calcium
scoring (10). Given the epidemic of diabetes that is upon us,
as well as the exorbitant health care expenditures that we
currently make, we will need to be diligent in carefully
assessing the risk, benefit, and cost of widespread screening.
If a high-risk patient is objectively identified, even in the
absence of symptoms, it will certainly be appropriate toproceed to more detailed high-risk assessment, with con-
sideration of medical versus revascularization therapy. Al-
though the study by Dagenais et al. (9) was a post hoc
analysis, it is consistent with prior studies over the past 30
years: prognosis in stable CAD is driven by objective
ischemia, not by the nature or magnitude of anginal
symptoms.
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